Sign In
Buy SNY
$44.38
+2.01 (+4.74%)
At Close: Jun 04, 2026
What This Drug News Could Mean for Sanofi Shareholders
09:00am, Sunday, 08'th Jan 2023
This star drug for Sanofi is one step closer to approval in the European Union for another chronic inflammatory disease.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
10:32am, Tuesday, 03'rd Jan 2023
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
SNY or LLY: Which Is the Better Value Stock Right Now?
12:48pm, Friday, 30'th Dec 2022
SNY vs. LLY: Which Stock Is the Better Value Option?
3 Big Drug, Biotech Stocks to Boost Your Portfolio in 2023
10:51am, Wednesday, 28'th Dec 2022
Here we discuss three big drug and biotech companies, Sanofi (SNY), GSK (GSK) and BioNTech (BNTX), which may prove to be good bets for your portfolio next year.
Sanofi's (SNY) Dupixent & Vaccines Make the Stock Attractive
12:02pm, Tuesday, 27'th Dec 2022
One can invest in Sanofi (SNY) due to the strong performance of Dupixent, above-market sales growth of the Consumer unit, consistent pipeline innovation and regular accretive collaboration deals.
3 Medical Dividend Stocks That Hit the Sweet Spot
08:15am, Monday, 26'th Dec 2022
These three offer high dividend yields and consistent revenue growth.
Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis
03:02pm, Monday, 19'th Dec 2022
The CHMP recommends approval of Sanofi (SNY) and partner Regeneron's Dupixent for the treatment of adults and adolescents with eosinophilic esophagitis.
Innate, Sanofi ink licensing deal for NK cells
08:17am, Monday, 19'th Dec 2022
Shares of Innate Pharma SA ADR [S: ipha] rallied 35.2% in premarket trading on Monday after the company said Sanofi SNY, -0.38% licensed its natural killer (NK) cell engager program as part of an alre
What Makes Sanofi (SNY) a New Buy Stock
01:32pm, Wednesday, 14'th Dec 2022
Sanofi (SNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SNY vs. LLY: Which Stock Is the Better Value Option?
12:47pm, Wednesday, 14'th Dec 2022
SNY vs. LLY: Which Stock Is the Better Value Option?
Why Small Biotech Kymera Just Snagged Sanofi's Interest And Surged 28%
09:58am, Wednesday, 14'th Dec 2022
Kymera unveiled promising results for its skin-disease treatment on Wednesday, snagging interest from Sanofi and sending KYMR stock flying. The post Why Small Biotech Kymera Just Snagged Sanofi's Inte
Sanofi: Positive Ruling On Zantac Litigation
04:15pm, Monday, 12'th Dec 2022
Positive court ruling on Zantac litigation. Horizon Therapeutics acquisition is already accretive in year 1. JNJ dropped out from the race.
Sanofi Says it does not intend to make an offer for horizon, leaving Amgen as sole bidder
01:49pm, Sunday, 11'th Dec 2022
French health group Sanofi said on Sunday that it no longer intends to make an offer for biotech company Horizon Therapeutics Plc HZNP.O, leaving Amgen Inc as the only remaining bidder.
Will This Potential Approval Be a Winner for Sanofi's Shareholders?
10:23am, Friday, 09'th Dec 2022
Sanofi and Regeneron's Dupixent moved closer to regulatory approval to treat another skin disease in the European Union.
GSK & Others Get Relief as US Court Dismisses Zantac Litigation
12:03pm, Thursday, 08'th Dec 2022
A U.S. district court dismisses thousands of lawsuits involving Zantac. Relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE).
